NASDAQ
3.10USD
+0.03 (+0.81%)
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
223.9M
P/E
—
EPS
—
Beta
0.33
52W range
1.21-3.6
Day range
3.09–3.10
Open
3.09
Prev close
3.08
Volume
300.7K
Avg volume
427.1K
Dividend
0.00
IPO
2021-07-01
https://www.defenseworld.net/2026/01/11/acumen-pharmaceuticals-inc-nasdaqabos-receives-average-rating-of-moderate-buy-from-brokerages.html · 1/11/2026+0.60
https://seekingalpha.com/article/4842680-acumen-pharmaceuticals-inc-abos-q3-2025-earnings-call-transcript · 11/12/2025+0.00
Acumen Pharmaceuticals Inc. operates as a biopharmaceutical entity in the clinical development stage, dedicated to discovering and advancing therapeutic solutions for Alzheimer's disease. A key focus for the company involves progressing ACU193, an investigational targeted immunotherapy drug candidate. This particular humanized monoclonal antibody is currently undergoing initial human testing in Phase I clinical trials, where it is designed to specifically target soluble amyloid-beta oligomers. The firm was established in 1996 and maintains its principal headquarters in Charlottesville, Virginia.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
